SpringWorks Therapeutics Current Ratio 2019-2022 | SWTX

SpringWorks Therapeutics current ratio from 2019 to 2022. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
SpringWorks Therapeutics Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2022-03-31 $0.36B $0.02B 15.32
2021-12-31 $0.38B $0.03B 12.78
2021-09-30 $0.43B $0.03B 15.41
2021-06-30 $0.47B $0.02B 20.29
2021-03-31 $0.48B $0.02B 25.71
2020-12-31 $0.51B $0.02B 29.15
2020-09-30 $0.28B $0.01B 21.87
2020-06-30 $0.29B $0.01B 30.76
2020-03-31 $0.31B $0.01B 36.55
2019-12-31 $0.33B $0.01B 27.68
2019-09-30 $0.35B $0.01B 33.79
2019-06-30 $0.00B 0.00
2019-03-31 $0.00B 0.00
2018-12-31 $0.00B 0.00
2018-09-30 $0.00B 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.907B $0.035B
SpringWorks Therapeutics Inc. is a clinical-stage biopharmaceutical company. It is focused on developing life-changing medicines for patients with severe rare diseases and cancer. The company's product pipeline consists of Nirogacestat and Mirdametinib which are in clinical stage. SpringWorks Therapeutics Inc. is based in Stamford, United States.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $162.107B 9.86
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.761B 16.99
Biohaven Pharmaceutical Holding (BHVN) United States $10.111B 0.00
Ginkgo Bioworks Holdings (DNA) United States $5.648B 0.00
Emergent Biosolutions (EBS) United States $1.770B 7.57
Arcus Biosciences (RCUS) United States $1.376B 34.89
Myovant Sciences (MYOV) United Kingdom $1.033B 0.00
Zymeworks (ZYME) Canada $0.397B 0.00
Gelesis Holdings (GLS) United States $0.345B 0.00
Ambrx Biopharma (AMAM) United States $0.157B 0.00
Enzo Biochem (ENZ) United States $0.110B 22.60
SQZ Biotechnologies (SQZ) United States $0.100B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00